Clinical characteristics and management of chronic spontaneous urticaria in patients refractory to H<sub>1</sub>-Antihistamines in Asia, Middle-East and Africa: Results from the AWARE-AMAC study.

Chu, Chia-Yu; Al Hammadi, Anwar; Agmon-Levin, Nancy; Atakan, Nilgun; Farag, Assem; Arnaout, Rand K; Kannenberg, Suretha; Kulthanan, Kanokvalai; Mubarak, Asmara; Zaitoun, Fares; Crowe, Susanne; Malfait, Sigrid; Cooke, Kathryn; Dekker, Elise L

Clinical characteristics and management of chronic spontaneous urticaria in patients refractory to H₁-Antihistamines in Asia, Middle-East and Africa: Results from the AWARE-AMAC study.

Chu, Chia-Yu; Al Hammadi, Anwar; Agmon-Levin, Nancy; Atakan, Nilgun; Farag, Assem; Arnaout, Rand K; Kannenberg, Suretha; Kulthanan, Kanokvalai; Mubarak, Asmara; Zaitoun, Fares; Crowe, Susanne; Malfait, Sigrid; Cooke, Kathryn; Dekker, Elise L.

Afiliação

Chu CY; Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
Al Hammadi A; Dermatology Center, Dubai Health Authority, Dubai, United Arab Emirates.
Agmon-Levin N; Clinical Immunology, Angioedema and Allergy Department, z Center for Autoimmune Diseases, Sheba Medical Centre, Ramat Gan, Israel.
Atakan N; Department of Dermatology, Hacettepe University, Ankara, Turkey.
Farag A; Dermatology Department, Faculty of Medicine, Benha University, Cairo, Egypt.
Arnaout RK; Department of Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
Kannenberg S; Division of Dermatology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Kulthanan K; Department of Dermatology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Mubarak A; Armed Forces Hospital, Royal Army of Oman, Muscat, Oman.
Zaitoun F; Allergy, Asthma & Immunology Center Specialty Clinics Center, Beirut, Lebanon.
Crowe S; Novartis Ireland Limited, Dublin, Ireland.
Malfait S; Novartis Pharma AG, Basel, Switzerland.
Cooke K; Novartis Pharma AG, Basel, Switzerland.
Dekker EL; Novartis Pharma AG, Basel, Switzerland.

World Allergy Organ J ; 13(4): 100117, 2020 Apr.

Article em En | MEDLINE | ID: mdl-32382379

Palavras-chave

AMAC, Asia Middle East and Africa; CINDU, Chronic inducible urticarial; CSU, Chronic spontaneous urticarial; CU, Chronic urticaria; Chronic spontaneous urticaria; CsA, Cyclosporine A; DLQI, Dermatology Life Quality Index; Efficacy; GCP, Good Clinical Practice; H1-AH, H1-antihistamines; HRCU, H1-antihistamines refractory chronic urticarial; HRQoL, Health-related quality of life; MONT, Montelukast monotherapy, or in combination with any H1-AH; OMA, Omalizumab monotherapy, or in combination with any H1-AH, with or without steroids; Omalizumab; PRO, Patient-reported outcomes; PhyGA-VAS, Physician Global Assessment of disease control-visual analog scale; QoL, Quality of life; Quality of life; SD, Standard deviation; SGC, Systemic glucocorticosteroids monotherapy, or in combination with any H1-AH; Second-generation antihistamines; UAS7, 7-day Urticaria Activity Score; fgAH, First-generation antihistamines monotherapy, or in combination with sgAH; sgAH, Second-generation antihistamines monotherapy approved dose: once daily or as needed; sgAHUP, Updosed second-generation H1-AH

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Observational_studies Aspecto: Patient_preference Idioma: En Revista: World Allergy Organ J Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google